Lannett said that its distribution agreement with Jerome Stevens Pharmaceuticals, or JSP, which expires on March 23, 2019, will not be renewed. “The Steinlauf family advised us this past Friday evening that they will not renew our agreement to distribute three JSP products: Butalbital, Aspirin, Caffeine with Codeine Phosphate Capsules USP, Digoxin Tablets USP and Levothyroxine Sodium Tablets USP, upon its expiration in March 2019,” said Tim Crew, CEO of Lannett. “The family has assured us of a continuous supply of the products through March of next year. These products remain valuable assets for us and are expected to significantly contribute to our financial performance in fiscal 2019.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.